TDOC Stock Recent News

Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.

Explore the exciting world of Teladoc (TDOC -0.13%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via virtual delivery. Telecare operates Australia's leading virtual care clinic and provides software solutions to the healthcare sector.

TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.

Teladoc Health remains a deep value play at $7, trading at just 5-6x EBITDA, but lacks a clear growth catalyst. Revenue and user metrics are declining across core segments, with BetterHelp and Chronic Care both losing momentum and failing to innovate. Recent acquisitions (UpLift, Catapult Health) have not meaningfully expanded Teladoc's platform or addressed its reliance on basic telehealth connections.

Teladoc's Q2 2025 earnings reaffirm strong free cash flow guidance, with the potential to reach $220 million in the next twelve months. Despite an attractive 7x next year's free cash flow valuation, revenue growth remains stagnant and threatens the bull case. Profitability and an improving balance sheet keep me tepidly bullish, but lack of growth and competitive pressures are major risks.

Teladoc Health, Inc. Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Michael Minchak - Vice President of Investor Relations Conference Call Participants Sarah Elizabeth James - Cantor Fitzgerald & Co., Research Division Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Jailendra P.

The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.

Hims & Hers and Teladoc Health are reshaping virtual care, but which has the edge in earnings growth and strategic expansion? Let's see.